Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Elcelyx splits business, Hi-Tech quarterly results, e-cigarettes study, FDA warning letters

This article was originally published in The Tan Sheet

Executive Summary

Elcelyx spins out weight-loss supplement; Hi-Tech OTCs get boost from Mag-Ox; e-cigarettes effectively help smokers quit; Irenda “use by” dates require support, FDA says; FDA warns Metagenics over medical food claims; McNeil recalls Motrin product; FDA approves Perrigo’s bubble gum version of Zyrtec.

You may also be interested in...

Hi-Tech Deal Broadens Akorn Consumer Business

Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.

Elcelyx Continues Work On Weight Loss Supplement With $7 Mil. Financing

The Series B funding enables the San Diego biotech to advance a weight loss supplement to the cusp of commercialization. Elcelyx, also moving a delayed-release formulation of diabetes drug metformin into mid-stage trials, so far has received some $20 million in venture capital.

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts